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An increasingly accepted concept is that the progression of colorectal cancer is
accompanied by epithelial–mesenchymal transition (EMT). In our study, in order
to characterize the properties of EMT in 16 colorectal cancer cell lines, the cells
were first orthotopically implanted into nude mice, and the tumors in vivo, as
well as cells cultured in vitro, were immunostained for EMT markers. The
immunostaining revealed that seven of the cells had an epithelial phenotype
with a high expression of E-cadherin, whereas other cells showed opposite pat-
terns, such as a high expression of vimentin (CX-1, COLO205, CloneA, HCT116,
and SW48). Among the cells expressing vimentin, some expressed vimentin in
the orthotopic tumors but not in the cultured cells (SW480, SW620, and
COLO320). We evaluated these findings in combination with microarray analyses,
and selected five genes: CHST11, SERPINI1, AGR2, FBP1, and FOXA1. Next, we
downregulated the expression of SERPINI1 with siRNA in the cells, the results of
which showed reverse-EMT changes at the protein level and in the cellular mor-
phology. Along with immunohistochemical analyses, we confirmed the effect of
the intracellular and secreted SERPINI1 protein of SW620 cells, which supported
the importance of SERPINI1 in EMT. The development of therapeutic strategies
targeting EMT is ongoing, including methods targeting the transforming growth
factor-b signaling pathway as well as the Wnt pathway. SERPINI1 is an important
regulator of EMT. Our findings help to elucidate the signaling pathways of EMT,
hopefully clarifying therapeutic pathways as well.
C olorectal cancer is the third most commonly diagnosedmalignant disease worldwide and the second most com-
mon cause of cancer mortality; approximately 694 000 deaths
are attributed to this disease worldwide annually.(1,2) Distant
metastases are responsible for the majority of cancer-related
deaths in CRC patients, and the presence of stage IV carci-
noma with distant metastasis is correlated with a dramatic drop
in the 5-year survival rate to 10%.(3,4)
An increasingly accepted concept is that CRC progression is
accompanied by a cellular pathway often referred to as EMT,
in which epithelial cells lose many of their epithelial character-
istics and acquire properties typical of mesenchymal cells. In
the 1980s, Greenburg and Hay reported EMT-associated
changes in cell phenotypes and mesenchymal states in adult
and embryonic epithelia.(5) Three types of EMT were catego-
rized at the Cold Spring Harbor EMT Meeting in 2008, among
which type 3 EMT was defined as the formation of migratory
metastatic tumor cells by epithelial carcinoma cells.(6,7) Epithe-
lial–mesenchymal transition is characterized by the loss of
E-cadherin expression and the gain of expression of mesenchy-
mal markers, such as vimentin, b-catenin, and N-cadherin.
Epithelial–mesenchymal transition also results in the acquisi-
tion of other properties involved in the progression of carci-
noma, such as an increased capability to migrate, a higher
resistance to apoptosis, and acquiring the properties of stem-
ness.(8,9) E-cadherin is regulated by various signal networks,
such as the transcription factors Snail, Slug, TWIST, SIP1
⁄ZEB2, and deltaEF1 ⁄ZEB1, which can directly bind the E-
cadherin promoter and repress E-cadherin transcription.(10) In
the tumor microenvironment, EMT is triggered by a diverse
set of stimuli, including growth factor signaling and tumor–
stromal cell interactions.(11) The hypoxic microenvironment
common to cancer cells is also an important factor in the
induction of the EMT, a key link in cancer progression.(12)
Ectopic s.c. tumor models have been used extensively in the
past; however, these models are limited by the paucity of pri-
mary relevant CRC models. However, orthotopic models offer
the advantage of allowing for the evaluation of tumor growth
in the tissue of origin and metastatic site formation.(13) In our
previous study, we confirmed that the orthotopic implantation
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of human CRC cell lines is a useful model for mimicking the
behavior of human CRC.(14) This study aims to identify novel
EMT-associated genes as therapeutic targets of invasive tumor
cells and metastasis. To identify genes possibly involved in the
EMT of CRC, we analyzed EMT-associated changes using an
orthotopic implantation method in vivo and immunostaining of
the orthotopic tumors and surgically resected colon cancer tis-
sues in combination with cDNA microarray analyses of gene
expression profiles.
Materials and Methods
Cell lines and culture conditions. Human CRC cancer cell
lines were provided by ATCC (Manassas, VA, USA), Riken
BioResource Center (Tsukuba, Japan), and Cell Resource Cen-
ter for Biomedical Research, Institute of Development, Aging
and Cancer, Tohoku University (Sendai, Japan). Sixteen CRC
cell lines successfully authenticated for origin and purity were
selected for this study.
In vivo orthotopic implantation mouse model. All of the pro-
cedures for the orthotopic implantation mouse model were
described in our previous report.(14) At 8 weeks after inocula-
tion, the mice were killed and postmortem examinations were
carried out.
Immunocytochemistry. The cell pellets were resuspended in
fibrinogen (Mitsubishi Tanabe Pharma Corp., Osaka, Japan)
PBS solution, and clotting was induced by adding thrombin
(Mochida Pharmaceutical Corp., Osaka, Japan). Each of the
cell clots was placed in a tissue cassette and fixed in 10% for-
malin for 24 h. Immunostaining was carried out using the
same technique as that used for immunohistochemistry.
Immunohistochemistry. Tissue samples obtained from the
orthotopically implanted tumors were fixed in IHC Zinc Fixa-
tive (Becton Dickinson Biosciences, San Jose, CA, USA) and
embedded in paraffin blocks. Then the blocks were cut serially
at 4-lm thickness and H&E staining was used to assess tumor
morphology. The Histofine Mousestain Kit (Nichirei Bio-
sciences Inc., Tokyo, Japan) was used according to the univer-
sal immunoenzyme polymer method. The antigen–antibody
complex was visualized with 3,30-diaminobenzidine solution
(1 mM 3,30-diaminobenzidine, 50 mM Tris–HCl buffer [pH
7.6], and 0.006% H2O2) and counterstained with hematoxylin.
The primary antibodies were as follows: mAbs for E-cadherin
(clone 4A2C7; Life Technologies, Carlsbad, CA, USA),
vimentin (clone V9; Dako, Carpinteria, CA, USA), SERPINI1
(polyclonal HPA001565; Sigma-Aldrich, St. Louis, MO,
USA), and CHST11 (polyclonal HPA052828; Sigma-Aldrich).
As a negative control, normal mouse IgG was used instead of
the primary antibodies. To determine conditions of immunos-
taining for E-cadherin, CK20, and b-catenin, normal colonic
tissues with epithelial cells were used as a positive control. In
regards to vimentin, gastrointestinal stromal tumors were used
as a positive control. In immunostaining of the SERPINI1 and
CHST11, normal duodenal tissues with epithelia and cerebrum
were used as a positive control, respectively. In immunostain-
ing of orthotopic tumors in mice, the immunostaining of nor-
mal epithelial cells in corresponding specimens was assessed
as an internal control.
Immunostaining scoring. To semiquantify the E-cadherin and
vimentin expressions, the immunostained slides were scored
according to the criteria proposed by Masunaga et al.(15)
Briefly, the staining intensity was scored as 0 (negative), 1
(weak), 2 (medium), or 3 (strong). The extent of staining was
scored as 0 (0%), 1 (1–25%), 2 (26–50%), 3 (51–75%), or 4
(76–100%) according to the proportion of positively stained
areas in relation to the area of the whole tumor. The sum of
the intensity and extent scores was used as the final staining
score (0–7).
cDNA microarray. Gene expression profiles were obtained for
16 CRC cell lines. The CodeLink Uniset Human 20KI Expres-
sion Bioarray (from GE Healthcare Life Sciences, now
Applied Microarrays, Tempe, AZ, USA) was used to carry out
the cDNA microarray analysis. The procedures have been pre-
viously described.(14) All of the microarray raw data were
deposited in the Gene Expression Omnibus at the NCBI under
accession number GSE49811.
Data analysis and selection of differentially expressed
genes. Analysis of raw microarray data was carried out with R
statistical package version 2.15.1 (The R Foundation for Statis-
tical Computing, Vienna, Austria). For comparisons among
multiple arrays, probes were quantile-normalized across arrays.
We searched for genes differentially expressed among epithe-
lial, EMT, and mesenchymal phenotypes using moderated t-
statistics in Bioconductor software, controlled by false discov-
ery rate(16) < 106 and log2[fold change] > 1.0. Information
was obtained from the NCBI site and HPA site by the Royal
Institute of Technology (Stockholm, Sweden) for the differen-
tially expressed genes is summarized in Table 1.
Small interfering RNA transfection. The siRNA oligonu-
cleotide for SERPINI1 and CHST11 used in this study was the
Stealth RNAi siRNA Duplex Oligoribonucleotide (Life Tech-
nologies). The sequences of siRNA against SERPINI1
(SERPINI1–HSS107974) were as follows: sense 50-GGCUG
UGCUGUAUCCUCAAGUUAUU-30 and antisense 50-AAUAA
CUUGAGGAUACAGCACAGCC-30. The siRNA sequences
against CHST11 (CHST11–HSS121327) were as follows: sense
50-CCCACCUAUGCAAAGUCUACGAGAA-30 and antisense
50-UUCUCGUAGACUUUGCAUAGGUGGG-30. The cells
were plated in 6-well plates, and the siRNAs were transfected
into cultured cells with Lipofectamine RNAiMAX (Life Tech-
nologies) according to the manufacturer’s instructions.
Real-time RT-PCR. The experiments were carried out using
the RNeasy Mini Kit (Qiagen, Valencia, CA, USA), Prime-
Script RT-PCR Kit (Takara Bio, Kyoto, Japan), and SYBR
Premix Ex Taq II, ROX plus (Takara Bio) on an ABI StepOne
Plus (Life Technologies) according to the manufacturer’s pro-
tocols. GAPDH was applied as the internal control. The pri-
mers used for PCR are listed in Table S1. The results were
calculated using the 2ΔΔCt method.
Western blot analysis. Protein was extracted from the cells
using Pierce RIPA Buffer (Thermo Fisher Scientific, Rockford,
IL, USA) with the cOmplete, EDTA-free Protease Inhibitor
Cocktail (Roche Diagnostics, Mannheim, Germany). A total of
20 lg whole cell extracts was loaded on mini protean TGX 4–
15% gels (Bio-Rad, Hercules, CA, USA) and transferred using
the Trans-Blot Turbo Blotting System (Bio-Rad). The mem-
branes were probed with the following primary antibodies:
mAbs for E-cadherin (clone 24E10; Cell Signaling Technol-
ogy, Beverly, MA, USA), vimentin (clone D21H3; Cell Signal-
ing Technology), Snail (clone C15D3; Cell Signaling
Technology), SERPINI1 (clone 1D10; Sigma-Aldrich),
CHST11 (clone 1H3; Sigma-Aldrich), or GAPDH (clone
D16H11; Cell Signaling Technology) as a control at 4°C over-
night. The secondary antibodies were peroxidase-coupled goat
anti-rabbit or anti-mouse antibodies and detected with Clarity
Western ECL Substrate (Bio-Rad), and the protein bands were
visualized using the ImageQuant LAS 4000 mini system (GE
Healthcare Life Sciences).
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Immunofluorescence staining and confocal laser microscopy.
Cells were seeded in 2-well plates with glass coverslips (Asahi
Techno Glass Corp., Tokyo, Japan). The cells were fixed in
4% paraformaldehyde before blocking in 5% normal goat
serum and 0.3% Triton X-100 in PBS. The cells were incu-
bated with anti-E-cadherin antibodies (clone 24E10) at 4°C
overnight, washed, then incubated with Alexa Fluor 488 sec-
ondary antibodies (Life Technologies) in the dark. The anti-
bodies were diluted in 1% BSA and 0.3% Triton X-100 in
PBS according to the manufacturer’s instructions. The cells
were rinsed in PBS, and the cell nuclei were stained with
DAPI (Life Technologies). The slides were examined under a
confocal laser-scanning microscope (C2si; Nikon, Tokyo,
Japan).
Surgically resected colon cancer tissues. Primary colon cancer
tissue specimens were obtained from 49 patients who had been
diagnosed with stage I or stage IV CRC according to the 2nd
English Edition of the Japanese Classification of Colorectal
Carcinoma.(17) To achieve an accurate diagnosis by immunos-
taining, tissue samples from stage I patients with limited num-
bers of cancer cells were excluded from the analysis. All of
the patients had undergone operations at Tohoku University
Hospital (Sendai, Japan), from 2008 to 2012. Written informed
consent was obtained from all patients.
Sample preparation of culture supernatant for SDS-PAGE. For
each of the cell lines, 5 9 106 cells were seeded and cultured
for 24 h. The cells were washed with PBS, incubated with
serum-free RPMI medium for 1 h, washed again with PBS,
and incubated for 48 h in serum-free RPMI medium. The cul-
ture media were centrifuged at 1500 g to remove cell debris,
and were concentrated 20-fold using a PAGE Clean Up Kit
(Nacalai Tesque, Kyoto, Japan).
Results
Orthotopic tumors and immunostaining. The CRC cells were
implanted onto the cecal walls of nude mice, and all cell lines
were successfully implanted and proliferated. Eight weeks after
implantation, the mice were killed and the tumors were
excised and diagnosed macroscopically (Fig. 1a) and micro-
scopically (Fig. 1b). Immunostaining analyses were carried out
for the 16 CRC cell lines in both in vitro cultured cells and
the orthotopically implanted tumors (Fig. 1c). In the analyses,
E-cadherin and CK20 were immunostained as epithelial mark-
ers, and vimentin and b-catenin were immunostained as mes-
enchymal markers. In both the cultured cells and orthotopic
tumors, immunostaining for E-cadherin and CK20 showed a
positive correlation (data not shown). During the processes of
EMT, both vimentin staining and nuclear staining of b-catenin
were observed in CRC. However, no positive correlations were
observed between immunostaining for vimentin or b-catenin
because interpreting the results of b-catenin immunostaining
was difficult due to the diversity of immunostaining findings in
the cytoplasm and nuclei (data not shown). Hence, for the sub-
sequent analyses, vimentin was used as a mesenchymal marker
and E-cadherin was used as an epithelial marker.
Representative images of immunocytochemistry of the
in vitro cultured cells and immunohistochemistry of the ortho-
topic tumors are shown in Figure 1(c). In epithelial cells of
the colorectum, epithelial markers, such as E-cadherin, are
generally strongly expressed, whereas mesenchymal markers,
such as vimentin, are typically negatively expressed. In Fig-
ure 1(c), HT-29 is positive for E-cadherin and negative for
vimentin, as the majority of epithelial cells are, HCT116 is
positive for E-cadherin and is focally positive for vimentin in
the orthotopic tumors but negative in the cultured cells, and
SW480 is positive for vimentin and slightly positive for E-cad-
herin in both the cultured cells and orthotopic tumors.
“Epithelial,” “EMT,” and “mesenchymal” phenotypes. The
images of immunocytochemistry of the in vitro cultured cells
and immunohistochemistry of the orthotopic tumors in 16 cell
lines are summarized in Figure S1. Based on the immunostain-
ing, the sum of the intensity and extent (0–7) was scored as
described in Materials and Methods, and the scores for the 16
cell lines were summarized in Figure 2. In seven cell lines
(HT-29, SW948, T84, LoVo, HCT8, HCT15, and DLD-1),
E-cadherin was positive and vimentin was negative. In the
majority of other cell lines, the expression of E-cadherin was
retained. In five cell lines (CX-1, COLO205, CloneA,
HCT116, and SW48), vimentin was focally positive in the
orthotopic tumors and negative in the cultured cells (Fig. 2),
which supports the idea that the five cell lines acquired the
EMT phenotype following orthotopic implantation. Three cell
lines (SW480, SW620, and COLO320) were positive in both
the cultured cells and implanted tumors, which supports the
idea that the mesenchymal phenotype is present in these cells
in vitro and in vivo.
Based on the immunostaining results summarized in Fig-
ure 2, we classified the cell lines into three groups (Fig. 3a):
those expressing the “epithelial phenotype” (E-cadherin-posi-
tive and vimentin-negative), those expressing the “EMT phe-
notype” (focally vimentin-positive in orthotopic tumors and
Table 1. Epithelial–mesenchymal transition candidate genes
Official symbol Gene name
Tissue specificity from HPA database
Gene ontology from NCBI Gene database
Normal tissues Tumor tissues
SERPINI1 Serpin peptidase inhibitor,
clade I, member 1
Central nervous system Carcinoid Central nervous system development
Regulation of proteolysis
CHST11 Carbohydrate sulfotransferase 11 Male reproductive system Liver cancer Chondroitin sulfate biosynthetic process
AGR2 Anterior gradient 2 homolog Lung Stomach cancer –
FBP1 Fructose-1,6-bisphosphatase 1 Endocrine tissues Urothelial cancer Cellular response to drug and Mg ion
Negative regulation of Ras protein signal
transduction, cell growth and glycolysis
FOXA1 Forkhead box A1 Kidney, endocrine tissues Thyroid cancer Positive regulation of transcription from
RNA polymerase II promoter
Response to estradiol stimulus
–, no data; HPA, Human Protein Atlas.
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negative in cultured cells), and those expressing the “mes-
enchymal phenotype” (vimentin-positive in both cultured cells
and orthotopic tumors). The LS180 cell line was negative for
both E-cadherin and vimentin and therefore excluded from the
subsequent analyses.
cDNA microarray analysis. Using the microarray data that were
normalized and converted to log2 ratios, for each of the 15 cell
lines, we two-dimensionally plotted the expression levels of E-
cadherin and vimentin (Fig. 3b). The mRNA expression levels
that were determined with the cDNA microarray were validated
by a RT-PCR. The results revealed that the expressions of
E-cadherin and vimentin at mRNA levels showed a negative
correlation. The cells classified into the three groups based on
the immunostaining patterns (Fig. 3a) were closely plotted
again (Fig. 3b), which indicated that the expressions of E-cad-
herin and vimentin observed at the mRNA level on the cDNA
microarray analyses were closely related to those noted at the
protein level on immunostaining.
Next, we compared the gene expressions among two of the
three groups: the epithelial phenotype, EMT phenotype, and
E-cadherin Vimentin E-cadherin Vimentin


















Fig. 1. Immunostaining of cultured cells in vitro
and orthotopically implanted colorectal tumors. (a)
Macroscopic findings of the primary tumor (Tu). (b)
Histological findings of an orthotopically implanted
tumor. M, mucosa; MP, proper muscle layer. Scale
bar = 1 mm. (c) E-cadherin and vimentin were
immunostained in cultured cells in vitro (scale
bar = 25 lm) and serially sectioned, orthotopically


















Score Score Score Score
E-cadherin Vimentin
In vitro culture Tumor In vitro culture Tumor
Fig. 2. Immunostaining scores for expression of E-
cadherin and vimentin in cultured colorectal cancer
cells in vitro and the orthotopically implanted
tumors. Staining intensity was scored as 0
(negative), 1 (weak), 2 (medium), or 3 (strong). The
extent of staining was scored as 0 (0%), 1 (1–25%),
2 (26–50%), 3 (51–75%), or 4 (76–100%) according
to the proportion of positively stained areas in
relation to the area of the whole tumor. The sum
of the intensity and extent scores was used as the
final staining score (0–7) for each specimen. Names
of the cell lines were represented using three colors
to discriminate their phenotypic belongings shown
in Fig.3(15)
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mesenchymal phenotype (Fig. 3c). For example, in the com-
parison of the epithelial phenotype and the EMT phenotype,
55 genes were listed. The genes listed in each comparison are
summarized in Table S2. Furthermore, we explored genes that
were commonly listed in the three comparisons (Fig. 3d) and
identified five differentially expressed genes in common.
Among them, the expressions of the SERPINI1 and CHST11
genes were lowest in the epithelial phenotype and highest in
the mesenchymal phenotype. In contrast, the AGR2, FBP1,
and FOXA1 genes showed the opposite pattern. Information
obtained from the NCBI and HPA for these five genes is sum-
marized in Table 1.
Knockdown of SERPINI1 and CHST11 genes. Considering SER-
PINI1 and CHST11 to be candidate genes associated with
EMT, we knocked down these genes with siRNA. In the
experiments, we chose SW620 cells, in which vimentin is
highly expressed. First, the knockdown of SERPINI1 and
CHST11 with siRNA for each gene (si SERPINI1 and si
CHST11, respectively) was confirmed using RT-PCR (Fig. 4a).
Next, the downregulation of SERPINI1 and CHST11 at the
protein level using each siRNA was confirmed with Western
blotting (Fig. 4b). Subsequently, under knockdown of SER-
PINI1 and CHST11 using each siRNA, the induction of E-cad-
herin and suppression of vimentin and Snail at the protein
level was confirmed (Fig. 4b). In this experiment, suppression
of Snail was more evident under si SERPINI1 than under si
CHST11. Finally, the induction of E-cadherin in the SW620
cells under knockdown of SERPINI1 or CHST11 was con-
firmed with a confocal microscope based on the remarkable
expression of E-cadherin in the cellular membranes (green)
compared with that observed in the controls (Fig. 4c). Next,




Fig. 3. Expression analysis of the 16 colorectal cancer cell lines using cDNA microarray data. (a) Fifteen CRC cell lines were classified into three
subgroups. (b) Array-based normalized expression levels of the E-cadherin and vimentin genes were two-dimensionally plotted. (c) Differentially
expressed genes were selected based on a ratio of the log2-transformed values of the normalized expression levels between the two groups of
log2[fold change] > 1.0 and a false discovery rate < 10
6. (d) Differentially expressed genes in common among the three comparisons in (c) were
explored. EMT, epithelial–mesenchymal transition.
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alterations in the SW620 cells, with changes into an aggre-
gated form (Fig. 4d).
SERPINI1 and CHST11 immunostaining. To confirm the
expression and localization of the SERPINI1 and CHST11
proteins, orthotopic tumors and surgically resected colon can-
cer tissues were subjected to immunostaining. SERPINI1 was
strongly stained in all of the five orthotopic tumors with the
EMT phenotype (CX-1, COLO205, and others) and in some
of the tumors with other phenotypes (Figs 5,S2). However, it
was difficult to score the immunostaining of CHST11 (data
not shown). In addition, as shown in Figure 6, the cancer
cells at the invasive fronts were more strongly stained with
SERPINI1 compared to those in the central cancer regions;
this phenomenon was observed in several cell lines. To con-
firm the clinical significance, the SERPINI1 protein was
immunostained in surgically resected tissue samples from
colon cancer patients (Table S3). The median postoperative
follow-up time was 50.5 months (range, 10.6–62.7 months)
and all of the stage I patients survived without recurrence for
at least 3 years. In contrast, over 95% of the stage IV patients
experienced a recurrence and died within this period. The his-
tological features of stage IV tumors showed a lower degree
of differentiation (poorly differentiated (por) and moderately
differentiated (tub2) adenocarcinomas(17)). than stage I tumors.
Furthermore, the stage IV tumors were strongly immunos-
tained with SERPINI1 (Fig. 7a), and had a higher average
SERPINI1 score than the stage I tumors (4.7 vs 2.8; Fig. 7b).
In contrast, it was difficult to find patterns of CHST11
immunostaining with surgically resected cancer tissue speci-
mens (data not shown).
Secreted SERPINI1 in culture supernatants. As SERPINI1 is a
secreted protein, the levels of SERPINI1 protein in CSs from
15 types of cells were quantified with Western blotting
(Fig. 8a), which revealed that the levels of the SERPINI1 pro-
tein were positively correlated with those at mRNA levels in
the cells. In particular, the cells in the mesenchymal phenotype
and the EMT phenotype showed SERPINI1 expression in CSs;
of these cells, SW620 and COLO320 showed particularly high
expressions (Fig. 8a). Next, we examined the effect of secreted
SERPINI1 protein on the expression of E-cadherin in SW620
cells (Fig. 8b). Following downregulation of intracellular SER-
PINI1 using siRNA (si SERPINI1) (Fig. 8b, lanes 2–5), CSs
of the SW620 cells were replaced with either the CSs from si
SERPINI1-treated SW620 cells (Fig. 8b, lane 3) or the CSs
from si Control-treated cells (Fig. 8b, lanes 4 and 5 as dupli-
cated experiments) to examine the effect of the secreted SER-
PINI1 protein in the CSs. The expression level of intracellular
E-cadherin did not change with the treatment of the CSs from
the si SERPINI1-treated SW620 cells (Fig. 8b, lane 3), in
which supernatants secreted SERPINI1 protein was suppressed;
however, the expression of E-cadherin was downregulated
when the SW620 cells were treated with the CSs from si Con-
trol-treated cells (Fig. 8b, lanes 4 and 5), in which the levels



























































1.2 si Control 
si SERPINI1 
Fig. 4. Knockdown of SERPINI1 and CHST11 genes
in SW620 colorectal cancer cells. (a) Knockdown of
SERPINI1 and CHST11 was confirmed using real-time
RT-PCR. (b) Using Western blotting, the
upregulation of E-cadherin and downregulation of
vimentin and Snail under knockdown of SERPINI1
and CHST11 were confirmed. (c) Using confocal
microscopy, the induction of E-cadherin (green)
under knockdown of SERPIN1 and CHST11 was
confirmed. (d) SW620 cells morphologically
changed under knockdown of SERPINI1 and CHST11
into an aggregated form. si, knockdown using
siRNA.
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Discussion
During the process of cancer invasion and metastasis, malig-
nant epithelial cells lose their characteristics of cell polarity
and cell–cell adhesion, which causes their transition to the
mesenchymal phenotype. In this process, the expression of
EMT-associated genes, including E-cadherin, vimentin, b-cate-
nin, Snail, Slug, TWIST, and ZEB1, are diversely altered.
Among these genes, the suppression of E-cadherin is thought
to be one of the most crucial changes that occurs during
EMT,(18,19) and Snail plays an important role in both the
expression of E-cadherin and the induction of EMT and cell
proliferation.(20,21)
In our study, in order to confirm the phenotypic and molecu-
lar changes of CRC cells in the EMT, we used an orthotopi-
cally implanted tumor model in mice, rather than an ectopic
tumor model. In this study, we observed several important
findings regarding the EMT in CRC cells. First, using 16 types
of CRC cells, we clarified that some of the cells showed an
epithelial phenotype with a high expression of the epithelial
marker E-cadherin and a negative expression of vimentin,
whereas other cells showed the opposite pattern, that is, a high
expression of vimentin (Fig. 2). Another significant finding
was that five of the cell lines (CX-1, COLO205, CloneA,
HCT116, and SW48) showed a focal expression of vimentin
only following orthotopic implantation of the cells into nude
mice. Such information has not been previously reported and
should be very beneficial in future studies as the platform to
analyze the EMT in CRC cells. Second, we identified candi-
date genes important for EMT processes and selected five
genes, including SERPINI1, that we considered to be the most
important. We believe that this information will help to eluci-
date the molecular background of EMT. Furthermore, we
downregulated the expressions of the SERPINI1 and CHST11
genes to confirm their effects on SW620 cells and SW48 cells,
the results of which supported the notion that our strategies are
reasonable. Next, immunohistochemical analyses of the SER-
PINI1 and CHST11 proteins in orthotopic tumors and surgi-
cally resected colon cancer tissues showed that the
intracellular SERPINI1 protein should be important for EMT
(Figs 5–7,S2), but it was difficult to score the immunostaining













Fig. 5. Immunostaining for SERPINI1 in orthotopically implanted col-
orectal tumors. (a) Immunostaining for SERPINI1 was carried out in
serially sectioned, orthotopically implanted tumors (scale
bar = 100 lm). (b) Immunostaining for expression of SERPINI1. Stain-
ing intensity was scored as 0 (negative), 1 (weak), 2 (medium), or 3
(strong). The extent of staining was scored as 0 (0%), 1 (1–25%), 2
(26–50%), 3 (51–75%), or 4 (76–100%) according to the proportion of
positively stained areas in relation to the area of the whole tumor.
The sum of the intensity and extent scores was used as the final stain-
ing score (0–7) for each specimen. Names of the cell lines were repre-




Fig. 6. Immunostaining for SERPINI1 at the
invasive fronts of orthotopically implanted
colorectal tumors. Representative images of CX-1,
COLO205, CloneA, and HCT116 cells are shown. The
invasive fronts are indicated with arrows. The cells
at the invasive fronts show strong SERPINI1
immunostaining.
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As SERPINI1 has been reported to be a secreted protease,(22)
we examined the effects of secreted SERPINI1 protein on the
expression of E-cadherin in SW620 cells (Fig. 8), which sup-
ported the importance of both intracellular and secreted SER-
PINI1 proteins on the regulation of E-cadherin and the EMT.
With those findings, we believe that SERPINI1 is important
for further analyzing the molecular mechanisms of the EMT in
CRC cells and may be key targets for developing novel thera-
peutic strategies for treating CRC through the pathways of
EMT.
Serpin peptidase inhibitor, clade I, member 1 is a secreted
protease that inhibits tissue-type plasminogen activator and
plasmin.(22) Although information remains limited, the SER-
PINI1 gene has been reported to be related to malignancies.
For example, serum SERPINI1 levels have been reported to be
elevated in patients with hepatocellular carcinoma and
CRC.(23) In addition, Barderas et al.(24) reported that three pro-
teins, SERPINI1, growth differentiation factor 15, and S100
calcium binding proteins A8 ⁄A9, show potential as candidate
biomarkers for CRC diagnosis.
In investigating the EMT, it is important to clarify correla-
tions between the phenotypes of EMT and the original cell
properties, such as cellular morphology, degrees of cellular
atypia, and differentiation. In the present study, the immunos-
taining of SERPINI1 revealed two important points: in surgi-
cally resected stage IV tumors, the histological features were
less differentiated and the immunostaining of SERPINI1 was
stronger (Fig. 7); and the cancer cells at invasive fronts, which
were less differentiated than the cells in the central tumor
regions, showed stronger SERPINI1 immunostaining in several
cell lines (Fig. 6). These results support the hypothesis that
SERPINI1 plays important roles in EMT.
(a)
(b)
Stage I (T1N0M0)  Score: 5 Stage IV (T3N2M1)  Score: 6
Stage I (T1N0M0)  Score: 2 Stage IV (T3N0M1)  Score: 3
SERPINI1
SERPINI1
n:  number of cases
Fig. 7. Immunostaining for SERPINI1 in surgically
resected colon cancer tissues. (a) Representative
images of the immunostaining for SERPINI1 are
shown. (b) A summary of the SERPINI1
immunostaining scores in 49 colon cancer cases.
Staining intensity was scored as 0 (negative), 1
(weak), 2 (medium), or 3 (strong). The extent of
staining was scored as 0 (0%), 1 (1–25%), 2 (26–
50%), 3 (51–75%), or 4 (76–100%) according to the
proportion of positively stained areas in relation to
the area of the whole tumor. The sum of the
intensity and extent scores was used as the final
staining score (0–7) for each specimen.(15)
© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
on behalf of Japanese Cancer Association.
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Snail recruits the polycomb repressive complex 2, which
contains enhancer of zeste 2 polycomb repressive complex 2
subunit (EZH2), suppressor of variegation 3-9 homolog 1
(SUV39H1), and other factors for the transcriptional regulation
of SNAIL during the EMT.(25) In addition to those transcrip-
tion factors, multiple signaling pathways activate the
expression of Snail, including the TGF-b–SMAD pathway, the
Wnt–b-catenin pathway, the Notch pathway, and growth fac-
tors that act through receptor tyrosine kinases. However,
glycogen synthase kinase-3b-mediated Snail phosphorylation
inactivates the transcriptional activity of Snail. To elucidate
the regulatory mechanisms of Snail with SERPINI1, the
above-described pathways and factors must be functionally
analyzed in a future study. In a secretome study, Barderas
et al.(24) identified a large amount of secreted SERPINI1 in
supernatants from KM12SM and KM12C colon cancer cells.
In their study, the SERPINI1 protein was also precipitated and
functionally analyzed. Some secreted proteases, which include
the ADAMTS family and secreted forms of ADAM proteins,
have also been reported to have important roles in the invasion
of CRC.(26,27) It was therefore important to analyze secreted
SERPINI1 protein with such strategies.
Considering the recently accumulated results of research on
EMT, the development of therapeutic strategies targeting the
EMT is promising. A series of factors regulating EMT, such
as TGF-b, Snail, E-cadherin, vimentin, b-catenin, Slug,
TWIST, and ZEBI, are candidate targets for developing novel
strategies to cure malignancies, and novel candidates, such as
SERPINI1, may become targets as well. Garg(28) and Li
et al.(29) introduced therapeutic strategies targeting EMT in
their review articles. Recently, several inhibitors against TGF-
b signaling have been shown to have anti-invasive effects.
Among them, LY2109761 is a novel TGF-b receptor type I
and type II dual inhibitor with the potential to be used in ther-
apeutic approaches designed to suppress colon and pancreatic
cancer metastasis.(30)
In conclusion, in the present study with 16 CRC cell lines,
we were able to confirm the presence of epithelial, EMT, and
mesenchymal phenotypic changes in vivo. This model may
provide a platform for identifying elements that are important
in the process of EMT in the tumor microenvironment. Fur-
thermore, we identified SERPINI1 to be a novel EMT-asso-
ciated gene. Our data provide insight into the molecular
mechanisms underlying the induction of the EMT during CRC
progression, which may be of significance for developing new
therapeutic strategies for treating CRC.
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ADAM a disintegrin and metalloproteinase
ADAMTS a disintegrin and metalloproteinase with thrombospondin
motifs
AGR2 anterior gradient 2 homolog




deltaEF1 elongation factor 1-delta
EMT epithelial–mesenchymal transition
FBP1 fructose-1,6-bisphosphatase 1
FOXA1 forkhead box A1
HPA Human Protein Atlas
SERPINI1 serpin peptidase inhibitor, clade I, member 1
SIP1 smad binding protein 1
si knockdown with siRNA
TGF-b transforming growth factor-b
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Fig. 8. Effects of secreted SERPINI1 protein in culture supernatants
(CSs) of colorectal cancer cells. (a) With Western blotting the protein
levels of secreted SERPINI1 in the CSs from 15 cell lines were positively
correlated with the mRNA expression levels among those cells. (b) The
expression level of E-cadherin in SW620 cells did not change with the
treatment of CSs from si SERPINI1-treated cells (lane 3 vs lane 2); how-
ever, the expression of E-cadherin was downregulated when the cells
were treated with CSs from si Control-treated cells (lane 4 and lane 5
as duplicated experiments). EMT, epithelial–mesenchymal transition.
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